MindImmune is a pre-clinical stage company focused on neuro-inflammation, targeting Alzheimer's disease (AD) as initial clinical indication. The company's lead program is an antibody-based therapeutic, aiming to inhibit an innate immune response originating in the periphery which is triggered by AD pathology. The lead program is in late stage pre-clinical development, contemplating IND filing near-term. If successful in clinical development, the company's therapeutic strategy would represent a fundamental breakthrough for the AD field. MindImmune scientists are at the forefront in recognizing the therapeutic opportunities in targeting the immune system to treat brain disease. MindImmune is based in Kingston, RI and is building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to leverage the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to advance its drug development programs.
Company Details
- Employees
- 13
- Founded
- -
- Address
- 130 Flagg Rd, Kingston,rhode Island 02881,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.mindimmune.com
- HQ
- Kingston, Rhode Island
Mindimmune Therapeutics, Inc. Questions
Mindimmune Therapeutics, Inc.'s website is http://www.mindimmune.com
Mindimmune Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/mindimmune-therapeutics-inc.
Mindimmune Therapeutics, Inc. has
13 employees.
View email and phone details for 13
employees at Mindimmune Therapeutics, Inc..
Mindimmune Therapeutics, Inc.'s industry is
Biotechnology Research
Mindimmune Therapeutics, Inc.'s top competitors are
Neurotech Pharmaceuticals, Inc.,
Cerevance,
Bolden,
Bolden Therapeutics,
Mirai Bio,
Ri Bio,
Ri Life Science Hub,
Organogenesis,
Epivax, Inc.,
Prothena Corporation.
Mindimmune Therapeutics, Inc.'s categories are Biotechnology Research
Mindimmune Therapeutics, Inc.'s founding year is 2016
